RNA AVIDITY BIOSCIENCES INC revenue, earnings and financials

For the quarter ended December 31, 2025, AVIDITY BIOSCIENCES INC reported revenue of $860K (down 71.1% from a year earlier), net income of −$237M and diluted EPS of −$1.59; over the last four quarters revenue was $18.8M and net income −$685M; for the fiscal year ended December 2025 revenue was $18.8M, up 72.1% on the year before.

RNA annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $18.8M, gross profit n/a, operating income −$746M, net income −$685M (margin -3650.4%), EPS −$4.97
• Fiscal year ended Dec 2024: revenue $10.9M, gross profit n/a, operating income −$379M, net income −$322M (margin -2957.7%), EPS −$2.89
• Fiscal year ended Dec 2023: revenue $9.56M, gross profit n/a, operating income −$236M, net income −$212M (margin -2219.9%), EPS −$2.91
• Fiscal year ended Dec 2022: revenue $9.22M, gross profit n/a, operating income −$179M, net income −$174M (margin -1886.3%), EPS −$3.34
• Fiscal year ended Dec 2021: revenue $9.33M, gross profit n/a, operating income −$118M, net income −$118M (margin -1265.4%), EPS −$2.85

RNA quarterly revenue and earnings

• Quarter ended Dec 31, 2025 (from the annual report): revenue $860K (down 71.1% year over year), net income −$237M, EPS −$1.59
• Quarter ended Sep 30, 2025: revenue $12.5M (up 434.0% year over year), net income −$174M, EPS −$1.27
• Quarter ended Jun 30, 2025: revenue $3.85M (up 88.1% year over year), net income −$157M, EPS −$1.21
• Quarter ended Mar 31, 2025: revenue $1.57M (down 55.6% year over year), net income −$116M, EPS −$0.90
• Quarter ended Dec 31, 2024 (from the annual report): revenue $2.97M (up 35.6% year over year), net income −$102M, EPS −$0.80
• Quarter ended Sep 30, 2024: revenue $2.34M (down 17.1% year over year), net income −$80.4M, EPS −$0.65
• Quarter ended Jun 30, 2024: revenue $2.05M (down 11.7% year over year), net income −$70.8M, EPS −$0.65
• Quarter ended Mar 31, 2024: revenue $3.54M (up 58.7% year over year), net income −$68.9M, EPS −$0.79
• Quarter ended Dec 31, 2023 (from the annual report): revenue $2.19M (down 20.8% year over year), net income −$60.4M, EPS −$0.80
• Quarter ended Sep 30, 2023: revenue $2.82M (up 13.5% year over year), net income −$52.4M, EPS −$0.71
• Quarter ended Jun 30, 2023: revenue $2.32M (up 6.3% year over year), net income −$47.0M, EPS −$0.66
• Quarter ended Mar 31, 2023: revenue $2.23M (up 24.4% year over year), net income −$52.4M, EPS −$0.74
• Quarter ended Dec 31, 2022 (from the annual report): revenue $2.77M (up 49.5% year over year), net income −$50.5M, EPS −$0.89
• Quarter ended Sep 30, 2022: revenue $2.48M (up 14.7% year over year), net income −$43.6M, EPS −$0.82
• Quarter ended Jun 30, 2022: revenue $2.18M (down 16.5% year over year), net income −$45.7M, EPS −$0.92
• Quarter ended Mar 31, 2022: revenue $1.80M (down 33.6% year over year), net income −$34.2M, EPS −$0.71
• Quarter ended Dec 31, 2021 (from the annual report): revenue $1.85M, net income −$38.5M, EPS −$0.83
• Quarter ended Sep 30, 2021: revenue $2.16M, net income −$29.3M, EPS −$0.68
• Quarter ended Jun 30, 2021: revenue $2.61M, net income −$26.4M, EPS −$0.70
• Quarter ended Mar 31, 2021: revenue $2.70M, net income −$23.8M, EPS −$0.64

RNA cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$650M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$301M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$119M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$136M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$94.8M, share buybacks n/a

RNA balance sheet

• Dec 31, 2025: cash $383M, total assets $1.96B, total liabilities $269M, shareholders' equity $1.69B
• Sep 30, 2025: cash $350M, total assets $2.13B, total liabilities $248M, shareholders' equity $1.89B
• Jun 30, 2025: cash $244M, total assets $1.37B, total liabilities $176M, shareholders' equity $1.19B
• Mar 31, 2025: cash $254M, total assets $1.46B, total liabilities $130M, shareholders' equity $1.33B
• Dec 31, 2024: cash $220M, total assets $1.56B, total liabilities $139M, shareholders' equity $1.42B
• Sep 30, 2024: cash $370M, total assets $1.64B, total liabilities $137M, shareholders' equity $1.50B
• Jun 30, 2024: cash $576M, total assets $1.35B, total liabilities $126M, shareholders' equity $1.22B
• Mar 31, 2024: cash $471M, total assets $951M, total liabilities $121M, shareholders' equity $831M

What is RNA's revenue?

AVIDITY BIOSCIENCES INC reported $18.8M of revenue over its last four quarters, through December 31, 2025.

Is RNA profitable?

No. AVIDITY BIOSCIENCES INC lost $685M over the last four quarters.

What is RNA's EPS?

Diluted earnings per share over the last four quarters were −$4.97; −$1.59 in the latest quarter.

RNA ownership and insider trades · All stocks